

20 July 2026

South African patent grant in Fibromyalgia strengthens global intellectual property portfolio

- South African patent granted covering methods of treating fibromyalgia using psilocybin and psilocin-based treatments, significantly strengthens Entropy's global intellectual property estate
- Patent provides broad protection spanning treatment methods, dosing regimens, patient selection, clinical protocols, biomarkers, outcome measures and manufacturing
- Creates significant commercial exclusivity for psychedelic-based fibromyalgia therapies in South Africa, with claims devised to be difficult for competitors to design around
- Patent term extends to September 2043, supporting Entropy's long-term commercialisation and partnering strategy
- Grant expands Entropy's growing global IP portfolio supporting development of TRP-8803 (IV-infused psilocin) for large unmet medical needs

Melbourne, Australia – Entropy Neurodynamics Limited ('**Entropy Neurodynamics**' or the '**Company**') (**ASX: ENP**), a clinical-stage biotechnology company, is pleased to advise that it has been granted a South African patent covering methods of treating fibromyalgia using psilocybin. The patent has been granted under South African Patent No. 2025/01722, entitled "*Methods of Treating Fibromyalgia with Compositions Comprising Psilocybin.*"

The granted patent provides broad intellectual property protection covering the clinical use of psilocybin for the treatment of fibromyalgia, including therapeutic methods, dosing regimens, patient selection criteria, clinical assessment protocols, biomarkers, treatment outcome measures, integration therapy and manufacture.

Collectively, the claims establish a comprehensive intellectual property position designed to provide meaningful commercial exclusivity as Entropy advances its psychedelic development programs.

Fibromyalgia is a chronic pain disorder characterised by widespread musculoskeletal pain, fatigue, sleep disturbance and cognitive impairment. The condition affects millions of people globally and remains an area of significant unmet medical need, with currently available therapies providing limited efficacy for many patients.

The South African patent complements Entropy's broader IP strategy, which is focused on securing protection across key therapeutic indications and jurisdictions to maximise the long-term commercial value of its psychedelic medicine platform.

The South African Fibromyalgia treatment market was valued at US\$1.9Bn in 2025ⁱ, providing another potential large market opportunity for the Company. This patent



provides Entropy with IP protection until 11 September 2043, subject to the payment of annual renewal fees.

Management commentary:

CEO, Mr Jason Carroll said: *"This patent represents another important addition to Entropy's growing intellectual property portfolio and significantly strengthens our position in fibromyalgia, a large indication with substantial unmet clinical need."*

"Importantly, the claims extend well beyond simply protecting the use of psilocybin and related therapies. They encompass the broader therapeutic framework, including dosing protocols, patient selection, clinical assessments and treatment methodology, creating comprehensive, indication-level intellectual property protection that we believe will be difficult for competitors to replicate."

"As we continue to generate clinical evidence across our precision-controlled psychedelic platform, building a robust global patent estate remains a key strategic priority. Strong intellectual property enhances the long-term value of our development programs, supports future partnering opportunities and reinforces our commercial positioning as we seek to develop next-generation psychedelic therapies for patients with significant unmet medical needs."

This announcement has been authorised by the Board of Entropy Neurodynamics Limited.

– ENDS –

INVESTOR & MEDIA CONTACT

Jason Carroll

Chief Executive Officer
Entropy Neurodynamics Limited
jcarroll@tryptherapeutics.com

Henry Jordan

Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Entropy Neurodynamics Limited

Entropy Neurodynamics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The Company's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. Development of TRP-8803 follows a number of Phase 2a clinical trials using oral psilocybin for the treatment of Binge Eating Disorder, Irritable Bowel Syndrome and Fibromyalgia. Results from each of these trials demonstrated the clinical benefits of psychedelic therapy and will be used to further enhance the development of TRP-8803.

Register for updates

The Company encourages investors to register their details with Automic Group investor portal. This also provides shareholders with the opportunity to elect communication methods to electronic only. This can

be done via the following steps:

- Go to investor.automic.com.au
- If you're an existing user, log in with your username and password
- If you're a new user, click 'register', select 'Entropy Neurodynamics Limited'. Enter your Holding Number and postcode of the registered address on your holding. If your address is outside Australia, select the country. Follow the prompts to set up a username and password.
- Once you have created your account, you will need to update your communication method by clicking 'my details' under the 'profile' section of the investor portal account, then navigating to 'communication preferences' and select 'electronic only'.

Risks associated with Psilocin

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimen used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Entropy Neurodynamics as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of the Company's Replacement Prospectus available at www.asx.com.au These factors are not intended to represent a complete list of the factors that could affect Entropy Neurodynamics; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

ⁱ <https://mobilityforesights.com/product/south-africa-fibromyalgia-treatment-market>